The AGEs/RAGE Transduction Signaling Prompts IL-8/CXCR1/2-Mediated Interaction between Cancer-Associated Fibroblasts (CAFs) and Breast Cancer Cells

Cells. 2022 Aug 4;11(15):2402. doi: 10.3390/cells11152402.

Abstract

Advanced glycation end products (AGEs) and the cognate receptor, named RAGE, are involved in metabolic disorders characterized by hyperglycemia, type 2 diabetes mellitus (T2DM) and obesity. Moreover, the AGEs/RAGE transduction pathway prompts a dysfunctional interaction between breast cancer cells and tumor stroma toward the acquisition of malignant features. However, the action of the AGEs/RAGE axis in the main players of the tumor microenvironment, named breast cancer-associated fibroblasts (CAFs), remains to be fully explored. In the present study, by chemokine array, we first assessed that interleukin-8 (IL-8) is the most up-regulated pro-inflammatory chemokine upon AGEs/RAGE activation in primary CAFs, obtained from breast tumors. Thereafter, we ascertained that the AGEs/RAGE signaling promotes a network cascade in CAFs, leading to the c-Fos-dependent regulation of IL-8. Next, using a conditioned medium from AGEs-exposed CAFs, we determined that IL-8/CXCR1/2 paracrine activation induces the acquisition of migratory and invasive features in MDA-MB-231 breast cancer cells. Altogether, our data provide new insights on the involvement of IL-8 in the AGEs/RAGE transduction pathway among the intricate connections linking breast cancer cells to the surrounding stroma. Hence, our findings may pave the way for further investigations to define the role of IL-8 as useful target for the better management of breast cancer patients exhibiting metabolic disorders.

Keywords: AGEs; IL-8; RAGE; breast cancer; cancer-associated fibroblasts.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / pathology
  • Cancer-Associated Fibroblasts* / metabolism
  • Diabetes Mellitus, Type 2* / metabolism
  • Female
  • Humans
  • Interleukin-8 / metabolism
  • Signal Transduction
  • Tumor Microenvironment

Substances

  • Interleukin-8

Grants and funding

Fondazione AIRC supported A.B. (IG n. 23369), E.M.D.F. (Start-Up Grant 21651) and M.M. (IG n. 21322). Ministero della Salute supported A.B., R.L. and M.M. (project RF-2019-12368937). M.F.S. was supported by the Italian Minister of University and Research (MIUR, D.D. n. 3407/2018)-PON R&I 2014–2020 “AIM Attrazione e Mobilità Internazionale”.